CNS Pharmaceuticals, Inc.
CNSP
Rank in Stocks
#23010
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily... CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
Share Price
$4.15
Last synced: 2026-11-17
Market Cap
$44.04M
Change (1 day)
19.25%
Change (1 year)
-39.86%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade CNS Pharmaceuticals, Inc. (CNSP)
Category
Healthcare
EPS for CNS Pharmaceuticals, Inc. (CNSP)
EPS as of September 2026 TTM: $-18.07
According to CNS Pharmaceuticals, Inc.'s latest financial reports, its current EPS (TTM) is $-18.07. At the end of 2025 the company had an EPS of $-35.75, an increase over its 2024 EPS of $-466.44.
EPS history for CNS Pharmaceuticals, Inc. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-18.07 | -49.45% |
| 2025 | $-35.75 | -92.34% |
| 2024 | $-466.44 | -99.69% |
| 2023 | $-150.11K | -55.39% |
| 2022 | $-336.50K | -32.02% |
| 2021 | $-495.03K | -3.35% |
| 2020 | $-512.21K | 141.47% |
| 2019 | $-212.12K | -47.55% |
| 2018 | $-404.42K | 3,270.97% |
| 2017 | $-12.00K | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -186.66% |
US
|
|
| $-7.08 | -60.82% |
US
|
|
| $-5.29 | -70.72% |
AU
|
|
| $21.56 | -219.31% |
NL
|
|
| $12.73 | -170.46% |
BE
|
Questions about CNS Pharmaceuticals, Inc.'s earnings per share (EPS)
What is CNS Pharmaceuticals, Inc.'s earnings per share (EPS)?
CNS Pharmaceuticals, Inc.'s earnings per share (EPS) over the last twelve months is $-18.07, as of Sep 2026.
What was CNS Pharmaceuticals, Inc.'s earnings per share (EPS) in 2025?
In 2025, CNS Pharmaceuticals, Inc.'s earnings per share (EPS) was $-35.75, compared with $-466.44 in 2024.
How has CNS Pharmaceuticals, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, CNS Pharmaceuticals, Inc.'s earnings per share (EPS) was highest in 2025 ($-35.75) and lowest in 2020 ($-512.21K).
How does CNS Pharmaceuticals, Inc.'s earnings per share (EPS) compare with similar companies?
CNS Pharmaceuticals, Inc.'s earnings per share (EPS) ($-18.07) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.